
Symeres acquires Oncolines, further strengthening its drug discovery and biology capabilities
Symeres, a leading global drug discovery Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), announces the acquisition of Oncolines, a Netherlands-based CRO that provides early biology services and cell-line profiling assays. Oncolines is Symeres’ third acquisition in the past ten months, and will take group revenues to over €100m.